Total Payments
$676.77
2024 Payments
$56.72
Companies
24
Transactions
33
Medicare Patients
4,392
Medicare Billing
$524,516
Payment Breakdown by Category
Food & Beverage$664.58 (98.2%)
Education$12.19 (1.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $664.58 | 32 | 98.2% |
| Education | $12.19 | 1 | 1.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $70.45 | 3 | $0 (2020) |
| JAZZ PHARMACEUTICALS INC. | $62.60 | 2 | $0 (2021) |
| Dexcom, Inc. | $56.72 | 2 | $0 (2024) |
| Eisai Inc. | $41.19 | 2 | $0 (2020) |
| Gilead Sciences, Inc. | $36.31 | 2 | $0 (2019) |
| GlaxoSmithKline, LLC. | $34.48 | 2 | $0 (2023) |
| Pharmacyclics LLC, An AbbVie Company | $34.00 | 2 | $0 (2019) |
| Abbott Laboratories | $27.67 | 2 | $0 (2022) |
| Seagen Inc. | $27.65 | 1 | $0 (2020) |
| Agios Pharmaceuticals, Inc. | $25.20 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $56.72 | 2 | Dexcom, Inc. ($56.72) |
| 2023 | $34.48 | 2 | GlaxoSmithKline, LLC. ($34.48) |
| 2022 | $31.45 | 2 | Boston Scientific Corporation ($19.81) |
| 2021 | $33.83 | 1 | JAZZ PHARMACEUTICALS INC. ($33.83) |
| 2020 | $142.82 | 7 | E.R. Squibb & Sons, L.L.C. ($50.33) |
| 2019 | $128.89 | 6 | JAZZ PHARMACEUTICALS INC. ($28.77) |
| 2018 | $169.07 | 9 | Takeda Pharmaceuticals U.S.A., Inc. ($21.77) |
| 2017 | $79.51 | 4 | Eisai Inc. ($23.67) |
All Payment Transactions
33 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/06/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $26.61 | General |
| Category: Endocrinology | ||||||
| 09/26/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $30.11 | General |
| Category: Endocrinology | ||||||
| 10/23/2023 | GlaxoSmithKline, LLC. | AREXVY (Drug), SHINGRIX | Food and Beverage | In-kind items and services | $21.20 | General |
| Category: RESPIRATORY | ||||||
| 07/18/2023 | GlaxoSmithKline, LLC. | AREXVY (Drug), SHINGRIX | Food and Beverage | In-kind items and services | $13.28 | General |
| Category: RESPIRATORY | ||||||
| 12/30/2022 | Boston Scientific Corporation | TheraSphere Y90 Glass Microspheres 10 GBq (Device) | Food and Beverage | In-kind items and services | $19.81 | General |
| Category: TheraSphere_PI | ||||||
| 06/30/2022 | Abbott Laboratories | PROCLAIM (Device) | Food and Beverage | In-kind items and services | $11.64 | General |
| Category: Neuromodulation | ||||||
| 01/19/2021 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Food and Beverage | Cash or cash equivalent | $33.83 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/14/2020 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $14.02 | General |
| Category: Hematology/Oncology | ||||||
| 10/19/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $38.14 | General |
| Category: Oncology | ||||||
| 09/21/2020 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $17.52 | General |
| Category: Oncology | ||||||
| 09/08/2020 | E.R. Squibb & Sons, L.L.C. | — | Education | Cash or cash equivalent | $12.19 | General |
| 08/17/2020 | Seagen Inc. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $27.65 | General |
| Category: Oncology | ||||||
| 07/18/2020 | Lilly USA, LLC | RETEVMO (Drug) | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: Oncology | ||||||
| 01/21/2020 | Bayer HealthCare Pharmaceuticals Inc. | Vitrakvi (Drug) | Food and Beverage | In-kind items and services | $15.70 | General |
| Category: Oncology | ||||||
| 12/16/2019 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $14.34 | General |
| Category: Oncology | ||||||
| 11/18/2019 | Agios Pharmaceuticals, Inc. | TIBSOVO (Drug) | Food and Beverage | In-kind items and services | $25.20 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2019 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Food and Beverage | Cash or cash equivalent | $28.77 | General |
| Category: ONCOLOGY | ||||||
| 09/16/2019 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: ONCOLOGY | ||||||
| 08/19/2019 | AbbVie, Inc. | Venclexta (Drug) | Food and Beverage | In-kind items and services | $19.50 | General |
| Category: Virology | ||||||
| 06/06/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.38 | General |
| 12/11/2018 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $21.77 | General |
| Category: Oncology | ||||||
| 11/19/2018 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $14.88 | General |
| Category: Oncology | ||||||
| 11/05/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $21.21 | General |
| Category: Oncology | ||||||
| 09/05/2018 | Abbott Laboratories | Axium INS DRG IPG (Device) | Food and Beverage | In-kind items and services | $16.03 | General |
| Category: Cardiac Arrhythmias and Heart Failure | ||||||
| 05/21/2018 | Taiho Oncology, Inc. | Lonsurf (Drug) | Food and Beverage | In-kind items and services | $18.88 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 23 | 721 | 944 | $91,350 | $19,506 |
| 2020 | 62 | 3,671 | 31,745 | $2.1M | $505,010 |
Total Patients
4,392
Total Services
32,689
Medicare Billing
$524,516
Procedure Codes
85
All Medicare Procedures & Services
85 procedure records from CMS Medicare Utilization — Page 3 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 13 | 55 | $7,425 | $1,665 | 22.4% |
| 99195 | Therapeutic removal of whole blood to correct blood level imbalance | Office | 2020 | 16 | 22 | $5,698 | $1,588 | 27.9% |
| 84153 | Psa (prostate specific antigen) measurement | Office | 2020 | 26 | 74 | $6,956 | $1,353 | 19.5% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2020 | 51 | 104 | $11,232 | $1,353 | 12.0% |
| 84165 | Protein measurement, serum | Office | 2020 | 66 | 125 | $12,375 | $1,327 | 10.7% |
| 96411 | Infusion of different chemotherapy drug or substance into a vein | Office | 2020 | 15 | 26 | $7,514 | $1,282 | 17.1% |
| 83550 | Iron binding capacity | Office | 2020 | 72 | 142 | $4,970 | $1,234 | 24.8% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 16 | 33 | $4,950 | $1,202 | 24.3% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 57 | 105 | $10,080 | $1,202 | 11.9% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 13 | 13 | $4,836 | $1,155 | 23.9% |
| 96360 | Hydration infusion into a vein 31 minutes to 1 hour | Office | 2020 | 21 | 35 | $8,960 | $989.55 | 11.0% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2020 | 75 | 160 | $4,960 | $958.96 | 19.3% |
| 83540 | Iron level | Office | 2020 | 72 | 141 | $3,807 | $906.81 | 23.8% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2020 | 26 | 47 | $4,653 | $885.80 | 19.0% |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2020 | 52 | 134 | $4,556 | $854.82 | 18.8% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2020 | 23 | 50 | $4,000 | $834.90 | 20.9% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2020 | 11 | 6,200 | $12,400 | $815.39 | 6.6% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2020 | 20 | 100 | $43,100 | $804.26 | 1.9% |
| 96402 | Hormonal anti-neoplastic chemotherapy administration beneath the skin or into muscle | Office | 2020 | 15 | 26 | $3,770 | $688.66 | 18.3% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2020 | 12 | 190 | $21,660 | $663.93 | 3.1% |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | Office | 2020 | 13 | 202 | $75,346 | $632.21 | 0.8% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2020 | 32 | 37 | $2,812 | $553.76 | 19.7% |
| 96361 | Hydration infusion into a vein | Office | 2020 | 27 | 47 | $3,525 | $530.25 | 15.0% |
| 85007 | Microscopic examination for white blood cells with manual cell count | Office | 2020 | 53 | 135 | $2,970 | $505.62 | 17.0% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2020 | 19 | 50 | $2,800 | $461.79 | 16.5% |
About Dr. Jerry Fain, M.D
Dr. Jerry Fain, M.D is a Hematology & Oncology healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1447293840.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jerry Fain, M.D has received a total of $676.77 in payments from pharmaceutical and medical device companies, with $56.72 received in 2024. These payments were reported across 33 transactions from 24 companies. The most common payment nature is "Food and Beverage" ($664.58).
As a Medicare-enrolled provider, Fain has provided services to 4,392 Medicare beneficiaries, totaling 32,689 services with total Medicare billing of $524,516. Data is available for 2 years (2020–2021), covering 85 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Austin, TX
- Active Since 06/14/2006
- Last Updated 01/13/2009
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1447293840
Products in Payments
- VYXEOS (Drug) $62.60
- Dexcom G6 Transmitter (Medical Supply) $56.72
- NINLARO (Drug) $44.56
- OPDIVO (Biological) $38.14
- AREXVY (Drug) $34.48
- Imbruvica (Drug) $34.00
- PADCEV (Biological) $27.65
- TIBSOVO (Drug) $25.20
- Halaven (Drug) $23.67
- TECENTRIQ (Biological) $21.54
- ADCETRIS (Biological) $21.21
- EMPLICITI (Biological) $20.12
- TheraSphere Y90 Glass Microspheres 10 GBq (Device) $19.81
- Venclexta (Drug) $19.50
- Prolia (Biological) $19.17
- Lonsurf (Drug) $18.88
- LIBTAYO (Biological) $17.70
- RETEVMO (Drug) $17.60
- Lenvima (Drug) $17.52
- Axium INS DRG IPG (Device) $16.03
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Austin
Dr. Debra Patt, Md, Mph, MD, MPH
Hematology & Oncology — Payments: $109,909
Hematology & Oncology $109,909
Uttam Rao
Hematology & Oncology — Payments: $19,966
Hematology & Oncology $19,966
Dr. Allison Gorrebeeck, Md, MD
Hematology & Oncology — Payments: $5,624
Hematology & Oncology $5,624
Dr. Richard Helmer, M.d, M.D
Hematology & Oncology — Payments: $3,540
Hematology & Oncology $3,540
Vinod Kondragunta
Hematology & Oncology — Payments: $3,490
Hematology & Oncology $3,490
Dr. Shubhada Shrikhande, Md, MD
Hematology & Oncology — Payments: $1,469
Hematology & Oncology $1,469